ResultsIQ › Latest results › CORONA Remedies Limited
CORONA Remedies Limited Q2 FY27 earnings call summary
NSE: CORONA · BSE: 544644
Earnings call of 2 Nov 2026, summarised by AI from the filing.
CORONA Remedies Q2 FY27 revenue ₹441 cr (+22.2%) with EBITDA margin 21.7%, and guides FY27 revenue growth of 15% and PAT growth of 20%.
Key takeaways
- Wokadine Integration and business-model change slower than expected; base sales maintained in Q2.
- Margin drag 400+ medical representatives added in Q4 FY26 weigh on EBITDA margin, which management expects to improve in coming years.
CORONA Remedies Limited Q2 FY27 results
As filed: Revenue ₹441 cr, EBITDA ₹96.0 cr, PAT ₹60.2 cr, EBITDA margin 21.8%.
Not scored. No result for the same quarter last year.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹422 cr, EBITDA ₹93.1 cr, PAT ₹60.1 cr, EBITDA margin 22.1%. Not scored. No result for the same quarter last year. Share price after the results: −0.9% in 28 days (Nifty 500: +0.3%).
- Q4 FY26: Revenue ₹353 cr, EBITDA ₹62.0 cr, PAT ₹45.1 cr, EBITDA margin 17.6%. Not scored. No result for the same quarter last year. Share price after the results: −1.2% in 30 days (Nifty 500: −2.5%).
- Q3 FY26: Revenue ₹342 cr, EBITDA ₹83.2 cr, PAT ₹41.3 cr, EBITDA margin 24.3%. Not scored. No result for the same quarter last year. Share price after the results: +5.9% in 30 days (Nifty 500: −1.9%).
Past price moves after results do not indicate future moves. Not a recommendation.
CORONA Remedies Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (2 Nov 2026), Results deck (30 Oct 2026), Results press release (30 Oct 2026)
- Q1 FY27: Earnings call (3 Aug 2026), Results deck (31 Jul 2026), Results press release (31 Jul 2026)
- Q4 FY26: Earnings call (12 May 2026), Results deck (11 May 2026), Results press release (11 May 2026)
- Q3 FY26: Earnings call (3 Feb 2026), Results deck (2 Feb 2026), Results press release (2 Feb 2026)
- Q2 FY26: Earnings call (5 Jan 2026), Results deck (3 Jan 2026), Results press release (2 Jan 2026)
Figures from the company's filings with NSE and BSE. Not investment advice.